Antihypertensive treatment and blood pressure control in patients with hypertension in daily clinical practice: a cross-sectional, multicenter, observational study in Egypt

Abstract

Objective: Management of hypertension in Egypt is difficult because of various reasons. This real-life study was conducted to determine BP control rate, treatment modalities, factors influencing the choice of antihypertensive drugs, physicians’ satisfaction with the treatment, and demographics of patients with uncontrolled BP who were treated for hypertension in daily clinical practice in Egypt.

Methods: This was a cross-sectional, multicenter, observational study conducted in patients treated for hypertension in out-patient private clinics in Egypt, during October 2011 to June 2012.

Results: Of 4139 patients with hypertension, 1509 (36.5%) had controlled BP and 2630 (63.5%) had uncontrolled BP. In BP controlled vs. uncontrolled groups, respectively, beta-blockers (41.7% vs. 41.0%) were the most frequently used antihypertensive agents, followed by diuretics (40% vs. 37.8%), angiotensin-converting enzyme inhibitors (35.3% vs. 34.9%), angiotensin receptor blockers (31.1% vs.19.4%), and calcium channel blockers (21.3% vs. 19.4%); the factors influencing the choice of antihypertensive therapy were “add-on therapy” (1.5% vs. 32.4%) and “change the current medication” (9.3% vs. 50.8%); physicians’ satisfaction with treatment was rated as “excellent” (31.6% vs. 3.2%) and “poor” (1.6% vs. 58%).

Conclusion: The majority of patients from Egypt had uncontrolled hypertension even after receiving treatment. This might increase awareness among physicians and enable them to prescribe appropriate treatment to patients with uncontrolled BP.

Key limitations: The questionnaire used in the study for the evaluation of patient/physician satisfaction level was not standardized and was based on the choice and practice of the physicians

Keywords:

• Angiotensin receptor blockers
• beta blockers
• Egypt
• hypertension

Transparency

Declaration of funding

The study was funded by Novartis Pharma Cairo, Egypt.

All authors participated in the development and writing of the paper and approved the final manuscript for publication.

Declaration of financial/other relationships

R.E.M. and A.O. have disclosed that they have received investigator fees related to the conduct of this study from Novartis and its affiliates.

CMRO peer reviewers on this manuscript have no relevant financial or other relationships to disclose.

Acknowledgments

The authors would like to thank Pinki Rajeev PhD and Madhavi Dokku PhD of Novartis Healthcare Pvt. Ltd., Hyderabad, India for medical writing and editorial assistance in the preparation of this manuscript.